Wednesday, April 1, 2026 – Thursday, April 2 - (MedPage Today) -- The FDA has approved a second oral GLP-1 receptor agonist for weight loss in adults with obesity or overweight and weight-related comorbidities.
A once-daily tablet, orforglipron (Foundayo) is indicated in conjunction with a...
Wednesday, April 1, 2026 – Thursday, April 2 - Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill version of Wegovy.
Wednesday, April 1, 2026 – WEDNESDAY, April 1, 2026 -- For adults with type 2 diabetes (T2D) who were not achieving glycemic control while receiving a stable dose of dulaglutide, switching to tirzepatide is associated with improvement in patient-reported outcomes (PROs)...
Wednesday, April 1, 2026 – Thursday, April 2 - Now Eli Lilly has an obesity pill, too.
On Wednesday, the FDA approved orforglipron, the agency announced. It will be sold as Foundayo, and Lilly has previously said it plans to ...
Wednesday, April 1, 2026 – Thursday, April 2 - Microdosing GLP-1 drugs is trending on social media and supported by some doctors, but experts warn the practice lacks a standard protocol and may undermine weight-loss results.
Wednesday, April 1, 2026 – Thursday, April 2 - Now Eli Lilly has an obesity pill, too.
On Wednesday, the FDA approved orforglipron, the agency announced. It will be sold as Foundayo, and Lilly said it plans to sell a ...
Wednesday, April 1, 2026 – Thursday, April 2 - While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.
Tuesday, March 31, 2026 – Wednesday, April 1 - INDIANAPOLIS, March 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide)...
Tuesday, March 31, 2026 – Wednesday, April 1 - PLAINSBORO, N.J., March 31, 2026 /PRNewswire/ -- Novo Nordisk today announced a new multi-month subscription program for Wegovy® (semaglutide) that provides eligible self-pay patients who enroll in the program through select telehealth providers...
Tuesday, March 31, 2026 – Wednesday, April 1 - (MedPage Today) -- GLP-1 medications showed a range of potential benefits and safety concerns in an umbrella review of non-cardiometabolic outcomes, though the data quality for many remained limited.
Across 60 meta-analyses that assessed 116 non...